China's NMPA to include Entyvio of Takeda Pharmaceutical for priority review in patients ages 2 and older with moderately to severely active ulcerative colitis (UC) (¥5741.0000, +93)
Takeda Pharmaceutical's ORZEYFUL (oveporexton) approved in China to treat narcolepsy type 1 (¥5493.0000, -59)
President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social
StreetAccount Sector Summary - Healthcare Post-Market
Takeda Pharmaceutical presents new data from two Phase 3 studies of zasocitinib in adults with moderate-to-severe PsO at 2026 AAD (¥5345.0000, 0)
CMS issues draft guidance on IRA drug price negotiation program for prices effective 2028
StreetAccount Summary - US unusual volume traders
Indonesia's Ministry of Health grants Takeda Pharmaceutical plasma fractionation license (¥5359.0000, 0)
InSilico Medicine Cayman TopCo enters up to $600M AI drug discovery collaboration with Takeda Pharmaceutical (HK$39.62, 0.00)
AC Immune reports interim 12-month data from Phase 1B/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease ($2.66, 0.00)
Powered by FactSet Research Systems Inc.